Limits...
S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats.

Guo Y, Cui L, Jiang S, Wang D, Jiang S, Xie C, Jia Y - Mol Med Rep (2016)

Bottom Line: Using Protein Analysis Through Evolutionary Relationships (PANTHER) analysis, 134 energy metabolism‑associated proteins, which comprised 20 carbohydrate metabolism‑associated and 27 lipid metabolism associated proteins, were identified as differentially expressed in the Ad‑S100A1‑EGFP hearts compared with controls.The majority of the proteins expressed in the Ad‑S100A1‑EGFP group were upregulated compared with the control group.These results were further validated using western blot analysis.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.

ABSTRACT
S100 Ca2+-binding protein A1 (S100A1) is an important regulator of myocardial contractility. The aim of the present study was to identify the underlying mechanisms of S100A1 activity via profiling the protein expression in rats administered with an S100A1 adenovirus (Ad‑S100A1‑EGFP) following acute myocardial infarction (AMI). LTQ OrbiTrap mass spectrometry was used to profile the protein expression in the Ad‑S100A1‑EGFP and control groups post‑AMI. Using Protein Analysis Through Evolutionary Relationships (PANTHER) analysis, 134 energy metabolism‑associated proteins, which comprised 20 carbohydrate metabolism‑associated and 27 lipid metabolism associated proteins, were identified as differentially expressed in the Ad‑S100A1‑EGFP hearts compared with controls. The majority of the differentially expressed proteins identified were important enzymes involved in energy metabolism. The present study identified 12 Ca2+‑binding proteins and 22 cytoskeletal proteins. The majority of the proteins expressed in the Ad‑S100A1‑EGFP group were upregulated compared with the control group. These results were further validated using western blot analysis. Following AMI, Ca2+ is crucial for the recovery of myocardial function in S100A1 transgenic rats as indicated by the upregulation of proteins associated with energy metabolism and Ca2+‑binding. Thus, the current study ascertained that energy production and contractile ability were enhanced after AMI in the ventricular myocardium of the Ad‑S100A1‑EGFP group.

No MeSH data available.


Related in: MedlinePlus

(A) Western blot analysis of the cardiac troponin I expression in the left ventricular tissue from the Ad-S100A1-EGFP and control groups. (B) Relative cardiac troponin I levels measured via western blotting. *P<0.01 vs. control. S100A1, S100 calcium binding protein A1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940056&req=5

f1-mmr-14-02-1538: (A) Western blot analysis of the cardiac troponin I expression in the left ventricular tissue from the Ad-S100A1-EGFP and control groups. (B) Relative cardiac troponin I levels measured via western blotting. *P<0.01 vs. control. S100A1, S100 calcium binding protein A1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Mentions: The 218 identified proteins were associated with the cytoskeleton, Ca2+-binding, cellular protein modifications, translation, catalytic activity, apoptosis, biological regulation and energy metabolism. The identified proteins included cTnI, MLC 3 and HSP70. Western blot analysis was performed to further validate the distribution of these proteins in the myocardial tissues of the Ad-S100A1-EGFP and control groups. The changes in the protein levels of cTnI (Fig. 1), MLC 3 (Fig. 2) and HSP70 (Fig. 3) were determined using western blot analysis. The western blot results were generally consistent with the changes detected by LTQ OrbiTrap. All proteomic experiments were performed at least twice to validate the reliability of the LTQ OrbiTrap results. Thus, the present proteomics data are reliable.


S100A1 transgenic treatment of acute heart failure causes proteomic changes in rats.

Guo Y, Cui L, Jiang S, Wang D, Jiang S, Xie C, Jia Y - Mol Med Rep (2016)

(A) Western blot analysis of the cardiac troponin I expression in the left ventricular tissue from the Ad-S100A1-EGFP and control groups. (B) Relative cardiac troponin I levels measured via western blotting. *P<0.01 vs. control. S100A1, S100 calcium binding protein A1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940056&req=5

f1-mmr-14-02-1538: (A) Western blot analysis of the cardiac troponin I expression in the left ventricular tissue from the Ad-S100A1-EGFP and control groups. (B) Relative cardiac troponin I levels measured via western blotting. *P<0.01 vs. control. S100A1, S100 calcium binding protein A1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Mentions: The 218 identified proteins were associated with the cytoskeleton, Ca2+-binding, cellular protein modifications, translation, catalytic activity, apoptosis, biological regulation and energy metabolism. The identified proteins included cTnI, MLC 3 and HSP70. Western blot analysis was performed to further validate the distribution of these proteins in the myocardial tissues of the Ad-S100A1-EGFP and control groups. The changes in the protein levels of cTnI (Fig. 1), MLC 3 (Fig. 2) and HSP70 (Fig. 3) were determined using western blot analysis. The western blot results were generally consistent with the changes detected by LTQ OrbiTrap. All proteomic experiments were performed at least twice to validate the reliability of the LTQ OrbiTrap results. Thus, the present proteomics data are reliable.

Bottom Line: Using Protein Analysis Through Evolutionary Relationships (PANTHER) analysis, 134 energy metabolism‑associated proteins, which comprised 20 carbohydrate metabolism‑associated and 27 lipid metabolism associated proteins, were identified as differentially expressed in the Ad‑S100A1‑EGFP hearts compared with controls.The majority of the proteins expressed in the Ad‑S100A1‑EGFP group were upregulated compared with the control group.These results were further validated using western blot analysis.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China.

ABSTRACT
S100 Ca2+-binding protein A1 (S100A1) is an important regulator of myocardial contractility. The aim of the present study was to identify the underlying mechanisms of S100A1 activity via profiling the protein expression in rats administered with an S100A1 adenovirus (Ad‑S100A1‑EGFP) following acute myocardial infarction (AMI). LTQ OrbiTrap mass spectrometry was used to profile the protein expression in the Ad‑S100A1‑EGFP and control groups post‑AMI. Using Protein Analysis Through Evolutionary Relationships (PANTHER) analysis, 134 energy metabolism‑associated proteins, which comprised 20 carbohydrate metabolism‑associated and 27 lipid metabolism associated proteins, were identified as differentially expressed in the Ad‑S100A1‑EGFP hearts compared with controls. The majority of the differentially expressed proteins identified were important enzymes involved in energy metabolism. The present study identified 12 Ca2+‑binding proteins and 22 cytoskeletal proteins. The majority of the proteins expressed in the Ad‑S100A1‑EGFP group were upregulated compared with the control group. These results were further validated using western blot analysis. Following AMI, Ca2+ is crucial for the recovery of myocardial function in S100A1 transgenic rats as indicated by the upregulation of proteins associated with energy metabolism and Ca2+‑binding. Thus, the current study ascertained that energy production and contractile ability were enhanced after AMI in the ventricular myocardium of the Ad‑S100A1‑EGFP group.

No MeSH data available.


Related in: MedlinePlus